BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 P&L / Income Statement

BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

218,250,000 US dollars

Cost of product sales

3,840,000 US dollars

Gross profit (calculated)

214,410,000 US dollars

Operating expenses (calculated)

115,945,000 US dollars

Income (loss) from operations

98,465,000 US dollars

Total other expense, net

negative 18,991,000 US dollars

Income (loss) before income taxes

79,474,000 US dollars

Income tax expense

1,079,000 US dollars

Net income (loss)

78,395,000 US dollars

License and other revenues - Neopharmed

54,513,000 US dollars

Research and Development - Neopharmed

1,216,000 US dollars

Undisclosed (calculated)

162,521,000 US dollars

Acquired in-process research and development

0 US dollars

Research and development

51,969,000 US dollars

Selling, general and administrative

63,976,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.